The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2021 | HDACIs in treating r/r PTCL
Won-Seog Kim, MD, PhD, Sungkyunkwan University, Seoul, South Korea, summarizes the results of the Phase IIb trial (NCT02953652) assessing HBI-8000, a histone deacetylase inhibitor (HDACI), in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). 55 patients were enrolled with a durable response rate reported. Patients with angioimmunoblastic T-cell lymphoma (AITL) additionally had a higher response rate, suggesting an increased role of HDACIs and demethylating agents in treating ATIL. This interview took place during the 2021 International Conference on Malignant Lymphoma (16-ICML).
